Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.
Q2 2026 Earnings Call July 17, 2026 7:00 AM EDTCompany ParticipantsLouise Tjeder - Head of Investor Relations & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results